Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J, Juloori A, Ginat D, Howard A, Chin J, Kochanny S, Foster C, Cipriani N, Lingen M, Izumchenko E, Seiwert TY, Haraf D, Vokes EE. Rosenberg AJ, et al. Among authors: foster c. Oral Oncol. 2021 Nov;122:105566. doi: 10.1016/j.oraloncology.2021.105566. Epub 2021 Oct 18. Oral Oncol. 2021. PMID: 34662771 Free PMC article. Clinical Trial.
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. Seiwert TY, et al. Among authors: foster cc. Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522. Ann Oncol. 2019. PMID: 30481287 Free article. Clinical Trial.
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes.
Foster CC, Seiwert TY, MacCracken E, Blair EA, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Gooi Z, Spiotto MT, Vokes EE, Haraf DJ. Foster CC, et al. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):662-671. doi: 10.1016/j.ijrobp.2020.04.014. Epub 2020 Apr 18. Int J Radiat Oncol Biol Phys. 2020. PMID: 32311416 Clinical Trial.
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. Seiwert TY, et al. Among authors: foster cc. Ann Oncol. 2019 Oct 1;30(10):1673. doi: 10.1093/annonc/mdz171. Ann Oncol. 2019. PMID: 31168601 Free article. No abstract available.
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Foster CC, et al. Clin Cancer Res. 2021 Oct 15;27(20):5510-5518. doi: 10.1158/1078-0432.CCR-21-0810. Epub 2021 Jun 24. Clin Cancer Res. 2021. PMID: 34168049 Clinical Trial.
3,225 results